Equity investment in UK companies reached £22.2bn in the first nine months of 2026, 21.5% more than in the same period of 2025, according to Beauhurst’s The Deal Q3 2026. The money is going into fewer, larger rounds: deal numbers fell 13.4% year on year, and rounds of £100m or more took 60.3% of all capital raised.
For most founders the market is tighter than the headline suggests. Seed deal numbers fell 27% in 2025, AI takes most new capital, and fintech funding is at a ten-year low. This briefing sets out the latest figures as of 3 November 2026, with the source and period for each, and the tax changes that apply now or from April 2027.
Key figures at a glance
| Measure | Figure | Source | Period |
|---|---|---|---|
| UK equity investment | £22.2bn, up 21.5% year on year | Beauhurst | January to September 2026 |
| UK equity deal numbers | Down 13.4%; average round up 41.9% to £5.42m | Beauhurst | January to September 2026 |
| Equity raised by UK smaller businesses | £12.3bn across 2,002 deals (value down 4%, deals down 17%) | British Business Bank | 2025 |
| Seed-stage deal numbers | Down 27% | British Business Bank | 2025 |
| UK venture capital investment | $6.8bn, down from $8.5bn in Q2 | KPMG Venture Pulse | July to September 2026 |
| UK startup funding | $17bn, up 102%; AI companies $12.6bn | Dealroom and HSBC Innovation Banking | January to June 2026 |
| UK fintech investment | £1.8bn across 205 deals | KPMG Pulse of Fintech | January to June 2026 |
| UK biotech venture capital | £2.8bn, of which £270m in Q3 | BioIndustry Association | January to September 2026 |
| Business births and deaths | 317,000 births, 280,000 deaths | ONS | 2024 |
| Five-year business survival | 38.4% of businesses born in 2019 | ONS | 2019 to 2024 |
| New company incorporations | 815,277, up 1.67% | Companies House | April 2025 to March 2026 |
Trackers use different currencies and deal definitions, so compare trends within one source rather than totals across sources.
More money, fewer deals
Beauhurst recorded £6.59bn across 1,168 deals in the third quarter of 2026, slightly ahead of Q3 2025 but below Q2, which was the strongest quarter for capital raised in more than four years. Concentration is the defining feature. Five companies took 48.5% of the capital raised in Q3, and rounds of £100m or more made up 64.9% of the quarter’s investment, against 32.3% a year earlier.
KPMG’s Venture Pulse for Q3 2026 shows UK venture investment softening to $6.8bn after what it calls four strong quarters, partly because of the usual summer slowdown. KPMG cites AI raises by CuspAI ($450m) and Olix ($317m) and notes that the UK has not seen a broad reopening of the exit market, particularly for IPOs.
For smaller businesses, the British Business Bank’s Small Business Equity Tracker 2026, published on 2 July 2026, found £12.3bn raised in 2025, down 4% on 2024, with deal numbers down 17%. London’s share fell to 57% of value and 48% of deals, from 60% and 49% in 2024. Investment more than doubled in the South West.
Which sectors are raising
AI. AI companies raised a record £5.4bn in 2025, 44% of all smaller-business equity investment, according to the British Business Bank. In the first half of 2026, Dealroom’s UK H1 2026 Innovation Update with HSBC Innovation Banking put UK AI funding at $12.6bn, more than four times the $2.8bn raised in H1 2025. The four largest rounds included Isomorphic Labs ($2.1bn) and Nscale ($2bn).
Fintech. UK fintech investment across venture, private equity and M&A fell to £1.8bn over 205 deals in the first half of 2026, down from £5.0bn a year earlier and the lowest half-year since 2016, according to KPMG’s Pulse of Fintech (24 August 2026). AI-focused fintechs bucked the trend, raising £445m across 79 deals. Hannah Dobson, KPMG UK’s head of fintech, said the second half was “likely to remain challenging for fundraising”.
Life sciences. UK biotech companies raised £2.8bn of venture capital in the first nine months of 2026, more than in any full year from 2022 to 2025, according to the BioIndustry Association’s Q3 2026 figures. Q3 alone was £270m, up 44% on Q3 2025 but well below Q2, which included Isomorphic Labs’ £1.6bn Series B. The UK has had no biotech IPO for 17 quarters.
Climate and energy. Tech Nation’s UK Climate Tech report, published on 25 November 2025, said investment in UK climate tech had fallen 67% since 2023, with late-stage megadeals largely gone.
Funding by stage
Beauhurst groups companies by seed, venture and growth stage rather than round letter; its venture stage broadly covers Series A and B.
- Seed. Seed deal numbers fell 27% in 2025 and seed companies took longer on average to secure funding, according to the British Business Bank. Beauhurst puts the median seed pre-money valuation at about £2.00m, flat since Q4 2025, though the AI seed median rose to £3.28m in Q3. First-time rounds made up 44.1% of deals in the first nine months of 2026.
- Venture (Series A and B). Beauhurst’s median venture-stage valuation rose 7% to £5.88m. Late-stage rounds took 68% of UK venture capital in H1 2026, up from 42% a year earlier and above the European average of 59%, according to Dealroom.
- Growth. Growth-stage investment into smaller businesses rose 10% to £5.7bn in 2025 despite a 4% fall in deals (British Business Bank). Beauhurst’s median growth-stage valuation fell to £17.0m from £23.8m.
Business formation and survival
The ONS Business demography, UK: 2024 release (20 November 2025) recorded about 317,000 business births and 280,000 deaths in 2024. The death rate of 9.8% was the lowest since 2016, but active businesses fell by about 11,000 to 2.86 million. Of businesses born in 2019, 38.4% were still trading five years later. The 2025 edition is due on 19 November 2026.
More recent data points to slower formation. The ONS quarterly series, still classed as official statistics in development, counted 69,895 business creations in Q3 2026, down 3.5% on Q3 2025, and 63,035 closures, down 1.1%. Companies House’s annual statistics (25 June 2026) show 815,277 incorporations in the year to March 2026, up 1.67%, while dissolutions rose 8.31% to 787,120. Identity verification became a legal requirement on 18 November 2025, and incorporation fees rose on 1 February 2026.
Tax and policy that affects founders now
SEIS and EIS
SEIS is unchanged: a company can raise up to £250,000, must have gross assets of no more than £350,000 and fewer than 25 full-time equivalent staff, and its trade must be three years old or less. Investors can claim up to 50% income tax relief on up to £200,000 a year.
EIS limits doubled from 6 April 2026, as set out in a GOV.UK policy paper of 26 November 2025:
- Annual EIS and VCT investment limit: £10m (£20m for knowledge-intensive companies), up from £5m and £10m.
- Lifetime limit: £24m (£40m for knowledge-intensive companies), up from £12m and £20m.
- Gross assets test: £30m before and £35m after the share issue, up from £15m and £16m.
- VCT income tax relief cut from 30% to 20%.
The Budget on 28 October 2026 did not change these limits. An HMRC impact note published that day sets out technical changes, including keeping EIS relief on the portion of an investment within the limits when a round exceeds them, and allowing SEIS and EIS shares to be issued on the same day.
R&D tax relief
For accounting periods beginning on or after 1 April 2024, the merged scheme gives a 20% expenditure credit. Loss-making SMEs spending at least 30% of total expenditure on R&D can instead use Enhanced R&D Intensive Support, with an 86% additional deduction and a 14.5% payable credit. The Budget removes the claim notification requirement for all R&D claims made on or after 1 April 2027, and HMRC will simplify the additional information form from autumn 2027.
Founders’ Relief, BADR and share options
A new Founders’ Relief will charge 10% capital gains tax on up to £10m of lifetime gains for founders and significant early investors in qualifying high-growth companies, for disposals on or after 6 April 2027. The eligibility consultation closes at 11:59pm on 30 November 2026. The Budget document also halves the Business Asset Disposal Relief lifetime limit from £1m to £500,000 from April 2027. Law firm DWF reports that CSOP will be renamed EMI2 from the same date, with the per-employee option limit doubling from £60,000 to £120,000. Founders planning an exit around April 2027 should take professional tax advice on timing.
Pensions and the Mansion House Accord
Under the Mansion House Accord of May 2025, 17 pension providers pledged to hold 10% of defined contribution default assets in private markets by 2030, including 5% in the UK. Tracking data from the ABI and Pensions UK, reported on 21 October 2026, showed £22.1bn (6.6%) in private markets at the end of 2025 and £11.1bn (3.3%) in the UK. Only £0.5bn of the UK share was in private equity, against £8bn in property. The Pension Schemes Act 2026, which received Royal Assent on 29 April 2026, gives the government a reserve power, usable from 2028 to 2032, to require at least 10% in growth assets and 5% in UK assets.
Sources
- Beauhurst: The Deal Q3 2026
- British Business Bank: Small Business Equity Tracker 2026
- KPMG: Venture Pulse Q3 2026
- Dealroom: UK H1 2026 Innovation Update
- KPMG UK: UK fintech funding drops to a decade low
- BioIndustry Association: Q3 UK biotech VC figures
- ONS: Business demography, UK: 2024
- GOV.UK: EIS and VCT investment limit increase and restructure
- HMRC: R&D tax reliefs, improving the customer experience
- GOV.UK: Founders’ Relief technical consultation

